Infertility Therapeutics Pipeline Analysis 2018

Share on facebook
Share on twitter
Share on linkedin
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Infertility is defined as the biological inability to conceive or contribute to conception, after having regular unprotected sex. According to the data published by the Department of Health and Human Services, approximately 10% to 15% of couples in the U.S. are infertile and have not conceived after at least one year of regular, unprotected sex. Infertility may have a single cause in one of the partners, or it could be the result of a combination of factors.

Download the sample report @ https://www.pharmaproff.com/request-sample/1142

Some of the causes of infertility are ovulation disorders in women, chemotherapy, radiotherapy, use of illegal drugs, and testicular infections in men.

Get the detailed analysis @ https://www.pharmaproff.com/report/infertility-therapeutics-pipeline-analysis

Risk factors associated with infertility are smoking, alcohol consumption, obesity, eating disorders, over-exercising, inactivity, sexually transmitted infections (STIs), mental stress, and exposure to some chemicals. Ferring International Center S.A. is in the process of developing FE 999310, for the treatment of infertility. Some of the companies having a pipeline of infertility include CellOxess LLC, TocopheRx, and others.